Effect of Influenza Vaccine in Patients with Kidney Transplant
1Surgery, Tomishiro Central Hospital, Tomishiro-shi, Okinawa, Japan
2Urology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan.
Meeting: 2018 American Transplant Congress
Abstract number: A178
Keywords: Infection, Kidney transplantation
Session Information
Session Name: Poster Session A: Kidney Transplant Goes Viral
Session Type: Poster Session
Date: Saturday, June 2, 2018
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Hall 4EF
Objective: In this study, we aimed to evaluate the effect of influenza vaccine in kidney transplant recipients.
Methods: We retrospectively studied 98 participants who underwent kidney transplantation (KTx) at our institution between March 2009 and May 2016. All patients had received adequate verbal instructions and provided written informed consent. All patients received tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone for maintenance immunosuppression after KTx. In accordance with the criteria of our institution, we included everolimus administration for the maintenance of immunosuppression after KTx. In kidney transplant patients, we compared the rate of influenza infection between the group treated with one or two shots of influenza vaccine (n=71) and the non-treatment group (n=27) for 8 months (between October 2016 and May 2017).
Results: Characteristics of patients in the treatment and non-treatment groups are shown in Table 1. The rate of diabetes mellitus in the treatment and non-treatment groups differed significantly (9.9%, 7/71 patients and 29.6%, 8/21 patients, respectively; p=0.015). Influenza infection occurred in the treatment and non-treatment groups at rates of 5.63% (4/71 patients) and 3.70% (1/27 patients), respectively (p=0.698).
| Table 1. Patients' Characteristics (Mean ± SD) | |||
| Treatment group (n=71) | Non-treatment group (n=27) | p value | |
| Male, n (%) | 46 (64.8) | 21 (77.8) | 0.217 |
| Age (years) | 50.4 ± 12.9 | 46.5 ± 14.4 | 0.201 |
| ABO-incompatible KTx, n (%) | 16 (22.5) | 8 (29.6) | 0.466 |
| Diabetes mellitus,n (%) | 7 (9.9) | 8 (29.6) | 0.015 |
| CyA, n (%) | 10 (14.1) | 2 (7.4) | 0.368 |
| EVR, n (%) | 29 (40.9) | 11 (40.7) | 0.993 |
| Period after KTx (months) | 45.5 ± 20.2 | 41.8 ± 24.6 | 0.446 |
| Current Scr level (mg/dL) | 1.26 ± 0.52 | 1.36 ± 0.67 | 0.415 |
| Current eGFR (mL/min/1.73 m[sup2]) | 49.7 ± 15.9 | 53.1 ± 27.9 | 0.453 |
| KTx, kidney transplantation; CyA, cyclosporine; EVR, everolimus; Scr, serum creatinine; eGFR, estimated glomerular filtration rate |
Conclusion: Among the kidney transplant patients who passed for a while after KTx, the group treated with one or two shots of influenza vaccine and the non-treatment group had almost the same influenza infection rates.
CITATION INFORMATION: Tsujimura K., Ota M., Ishida H., Tanabe K. Effect of Influenza Vaccine in Patients with Kidney Transplant Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Tsujimura K, Ota M, Ishida H, Tanabe K. Effect of Influenza Vaccine in Patients with Kidney Transplant [abstract]. https://atcmeetingabstracts.com/abstract/effect-of-influenza-vaccine-in-patients-with-kidney-transplant/. Accessed May 9, 2025.« Back to 2018 American Transplant Congress